ClinicalTrials.gg
RecruitingNCT06842537Updated Apr 30, 2025

Study of SYH2062 Injection in Healthy Chinese Volunteers

A Phase 1 interventional study of SYH2062 injection and SYH2062-Matching placebo in Healthy Chinese Volunteers, sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-04-30.

Sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacodynamics and pharmacokinetics of SYH2062 injection in healthy Chinese volunteers

Read the detailed description

A Phase 1, randomized, double-Blind, placebo-Controlled study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of SYH2062 injection after a single administration in healthy subjects

02

Conditions studied

  • Healthy Chinese Volunteers
03

In context

Lead sponsor

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. is the lead sponsor of 30 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must give before the trial, fully understand the content, process and possible adverse reactions, and voluntarily sign a written informed consent.
  2. Age of 18 - 55 years (inclusive).
  3. : 19.0-26.0 kg/m\^2 (inclusive), with a minimum weight of 50 kg (inclusive) for males and 45 kg (inclusive) for females.
  4. Has Systolic blood pressure (SBP) ≥100 mmHg and \<140 mmHg and diastolic blood pressure (DBP) ≥60 mmHg and \<90 mmHg at screening;
  5. The subjects can communicate well with the investigators and complete the trial according to protocol.

Exclusion criteria

Exclusion Criteria:

Allergic constitution, or known history of allergy to the components of the study drug or similar drugs.

2 Subjects with the following diseases of clinical significance (including but not limited to diseases of the circulatory system, diseases of the blood or hematopoietic system, diseases of the respiratory system, diseases of the endocrine system, diseases of the urinary system, diseases of the digestive system, neurological or mental diseases, infections, tumors, serious injuries).

3 Those who underwent major surgery within 6 months prior to initial administration, or who planned to undergo surgery during the study.

4 Blood loss or blood donation of more than 200 mL within 3 months prior to initial administration (except for female menstrual period), and/or donation within 2 weeks prior to initial administration.

5 Positive urine drug screening. 6 Those who smoked more than 5 cigarettes per day within 3 months prior to screening and/or did not agree to refrain from using any tobacco products during hospitalization.

7 Regular drinkers within 6 months prior to screening, i.e., those who drank more than 14 units of alcohol per week, and/or those who could not stop drinking alcohol during their hospitalization, and/or test positive for breath alcohol.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    SYH2062 injection

    Drug: SYH2062 injection

  • Placebo comparator
    SYH2062-Matching placebo

    Drug: SYH2062-Matching placebo

Interventions

  • DrugSYH2062 injection

    SYH2062 for sc injection

  • DrugSYH2062-Matching placebo

    Normal saline matching volume of SYH2062 doses will be administered

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    Time frame: up to approximately 12 months

Secondary outcomes

  1. Change from Baseline in Blood Angiotensinogen (AGT) Level

    Time frame: up to approximately 12 months

  2. Change from Baseline in in plasma renin concentration

    Time frame: up to approximately 12 months

  3. Change from Baseline in in plasma renin activity

    Time frame: up to approximately 12 months

  4. Change from Baseline in in angiotensin I

    Time frame: up to approximately 12 months

  5. Change from Baseline in in angiotensin II

    Time frame: up to approximately 12 months

  6. Change from Baseline in in plasma aldosterone

    Time frame: up to approximately 12 months

  7. To characterize the Cmax of single dose of SYH2062

    Time frame: Up to Day 3

  8. To characterize the AUC of single dose of SYH2062

    Time frame: Up to Day 3

  9. Number of Participants With Anti- SYH2062 Antibodies

    Time frame: up to approximately 3 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Dec 2025, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2025
First posted
Feb 24, 2025
StartActual
Mar 1, 2025
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Apr 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06842537
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Mar 1, 2025
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Apr 30, 2025

Study contacts

Wang Hongyun, Doctor
Contact
wanghy@pumch.cn
+8618611513192

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion